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Abstract 38 
Background: Studies of the associations between in utero 25-hydroxyvitamin D [25(OH) D] 39 
exposure and childhood asthma risk, wheeze and respiratory tract infections are inconsistent and 40 
inconclusive.  41 
 42 
Objectives: To assess the associations between 25(OH) D levels in cord blood or maternal 43 
venous blood and risk of offspring’s asthma, wheeze and respiratory tract infections. 44 
 45 
Methods: Data were derived from PubMed, EMBASE, Google Scholar, references from 46 
relevant articles, and de novo results from published studies until December, 2015.  Random-47 
effects meta-analysis was conducted among 16 birth cohort studies. 48 
 49 
Results: Comparing the highest to the lowest category of 25 (OH) D levels, the pooled ORs 50 
were 0.84 (95% CI, 0.70 to 1.01; P = 0.064) for asthma, 0.77 (0.58 to 1.03; P = 0.083) for 51 
wheeze, and 0.85 (0.66 to 1.09; P = 0.187) for respiratory tract infections. The observed inverse 52 
association for wheeze was more pronounced and became statistically significant in the studies 53 
that measured 25 (OH) D levels in cord blood (0.43, 0.29 to 0.62; P < 0.001).  54 
 55 
Conclusions: Accumulated evidence generated from this meta-analysis suggests that increased 56 
in utero exposure to 25 (OH) D is inversely associated with the risk of asthma and wheeze during 57 
childhood. These findings are in keeping with the results of two recently published randomized 58 
clinical trials of vitamin D supplementation during pregnancy.   59 
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Key Messages 60 
• Two recent randomized clinical trials suggest a non-significant protective effect of prenatal 61 
vitamin D supplementation on the risk of persistent wheeze/asthma in early childhood. 62 
However, the trials may be underpowered. 63 
• After meta-analyzing data from 16 birth cohorts, we show that increased in utero exposure 64 
to 25 (OH) D is inversely related to risk of offspring’s asthma and wheeze, but not 65 
respiratory tract infections.  66 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Capsule Summary 67 
• Combining data from 16 birth cohort studies, this meta-analysis suggests that in utero 68 
exposure to 25(OH) D is inversely associated with risk of offspring’s wheeze and asthma 69 
during childhood, supporting findings from two recent RCTs.  70 
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                  birth cohort studies 72 
Abbreviations used:  
25(OH) D: 25-hydroxyvitamin D 
CI: Confidence intervals 
CLIA: Chemiluminescence immunoassay 
ECL: Electrochemiluminescence 
EIA: Enzyme immunoassay 
HPLC: High-performance liquid chromatography 
HPLC-MS: High-performance liquid chromatography-tandem mass spectrometry 
HR: Hazards ratio 
LC-MS: Liquid chromatography-tandem mass spectrometry 
NOS: Newcastle-Ottawa quality assessment scale 
OR: Odds ratio 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
guidelines 
RIA: Radioimmunoassay 
RR: Relative risk 
RTI: Respiratory tract infection 
 73 
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INTRODUCTION 75 
Asthma, characterized by variable airway obstruction, wheeze, bronchial hyper-responsiveness 76 
and airway inflammation,1 is very common worldwide and usually starts in childhood.2 While 77 
allergic constitution, sensitization to allergens3-5 and/or familial history of allergic disease6 are 78 
recognized risk factors for asthma, studies also suggest that maternal vitamin D status during 79 
pregnancy may be associated with the risk of asthma in childhood.7,8 To date, some birth cohort 80 
studies have shown that vitamin D status may play an important role in the development of fetal 81 
lungs.9-11 Also, epidemiologic studies  have suggested that maternal vitamin D intake12, 13 as well 82 
as vitamin D levels in blood14-16 were inversely associated with respiratory tract infections and 83 
other wheezing illnesses, presumably because of its multiple immune effects including induction 84 
of antibacterial responses and modulation of T-lymphocytes to suppress inflammation.17,18 Data 85 
from randomized clinical trials are sparse, but two recently-published trials reported a non-86 
significant more than 20% reduced risk of persistent wheeze/asthma at age 0-3 years from 87 
prenatal vitamin D supplementation19,20 In addition to the relatively short follow-up period, the 88 
investigators acknowledged that the studies might be underpowered. 89 
 90 
A systematic review of 3 cohort studies qualitatively summarized the evidence suggesting a 91 
potential link between serum levels of vitamin D and the diagnosis of asthma in childhood.21 92 
Another systematic review of 23 published articles including 9 cross-sectional, 2 case-control, 93 
and 12 cohort studies in both children and adults suggested that higher serum levels of 25-94 
hydroxyvitamin D [25(OH) D] were associated with lower risk of asthma exacerbations, but 95 
provided little evidence on whether lower in utero exposure to 25(OH) D has a programming 96 
effect on development of asthma in childhood.22 Notably, neither of these reviews considered 97 
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wheeze and respiratory tract infections as outcomes. 98 
 99 
Since placental transfer of 25(OH) D is the major source of vitamin D in the developing fetus, 100 
we conducted this meta-analysis to quantitatively summarize the up-to-date literature to examine 101 
the overall associations between 25 (OH) D levels of cord blood or maternal venous blood and 102 
risk of childhood asthma, wheeze, and respiratory tract infections.  103 
 104 
METHODS 105 
Search strategy and selection criteria 106 
Two investigators (HF and PX) scrutinized publications independently based on the Preferred 107 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.23 The 108 
complete search process is outlined in Fig 1. First, PubMed [1966-] and EMBASE [1974-] were 109 
searched from inception to December 31, 2015 using the terms “vitamin D” and “lung disease or 110 
asthma or respiratory tract diseases” and “epidemiological studies” and “cohort / prospective or 111 
follow-up or longitudinal studies”. Second, Google Scholar was used to search for any other 112 
studies that were not identified from the aforementioned literature review. Third, the references 113 
from the retrieved articles were manually searched for possible additional studies. Conference 114 
abstracts and unpublished studies were not included. Finally, to get additional information, we 115 
requested de novo data specifically for this meta-analysis from some primary studies.24-26  116 
 117 
The following inclusion criteria were used in this meta-analysis: 1) English article; 2)  118 
prospective birth cohort design; 3) cord blood or maternal venous blood 25 (OH) D levels as 119 
exposure; 4) offspring’s asthma, wheeze or respiratory tract infections, which were diagnosed by 120 
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physicians or meeting the international guidelines, or the parents reported as outcomes; and 5) 121 
available data on the relevant odds ratio (OR) or relative risk (RR) or hazards ratio (HR) and the 122 
corresponding 95% confidence intervals (CIs).  123 
 124 
Quality assessment and data extraction 125 
Two investigators (HF and PX) independently evaluated the quality of each primary study based 126 
on the criteria derived from the Newcastle-Ottawa quality assessment scale (NOS) with a 127 
maximum score of 9 points.27 Any discrepancy was adjudicated by a third reviewer (KH). The 128 
NOS for cohort studies was divided into three groups: selection of cohort (4 points), 129 
comparability of cohort (2 points) and assessment of outcome (3 points). The quality of study 130 
was considered high or moderate if the sum score was ≥ 8 points or between 5-7 points, 131 
respectively We limited our meta-analysis to those studies that were rated as high or moderate 132 
quality. One study was excluded from the main analysis due to low quality.28 E Table 1 at the 133 
Online Repository shows the details of the study quality assessment.  134 
 135 
Data were extracted from all the eligible studies by two independent researchers (HF and PX) 136 
based on a standardized form, and any controversy was resolved through consensus by 137 
discussion with a third researcher (KH). From each included study, we extracted the following 138 
information: name of the first author, year of publication, the country of origin, study name, 139 
proportion of boys, duration of follow-up, numbers of participants/events, exposure assessment 140 
and categorization, outcome definition and assessment, adjusted covariates in the final model, 141 
and the OR / RR / HR estimates with corresponding 95%CIs for all categories and/or continuous 142 
exposure of interest.   143 
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 144 
To examine dose-response relationship, linear associations were standardized to per 10 nmol/L 145 
increment in blood 25 (OH) D levels. If the linear association was not reported in the primary 146 
study, we estimated it using Greenland and Longnecker’s generalized least square method if the 147 
participants and the events in each category were available, or using variance-weighted least-148 
squares estimation if this information was unavailable.29,30. If the highest exposure category was 149 
open-ended (e.g., >89 nmol/L), its upper limit was determined by assuming its range was the 150 
same interval as that of the adjacent category. Twelve out of 16 included studies reported ORs 151 
(95%CIs). In addition, we obtained de novo data for ORs (95%CIs) from two studies,25,26 and 152 
converted RRs (95%CIs) to ORs (95%CIs) in other two studies31,32  by using the formula: OR = 153 
[(1-P0)*RR/(1-RR*P0)], where P0 indicated the incidence of the outcome of interest in the non-154 
exposed/reference group.33  155 
 156 
Statistical analysis 157 
The ORs and corresponding 95%CIs extracted from individual studies were transformed into 158 
natural logarithms to normalize their distribution, stabilize the variances, and facilitate the 159 
calculation of its standard errors. The pooled ORs and corresponding 95%CIs for each outcome 160 
of interest were computed using a random-effects model by weighting the inverse of variance. To 161 
get the pooled association for risk of asthma and wheeze, we pooled the two outcomes within 162 
each study first using a random-effects model if the study reported both of the two outcomes. 163 
The heterogeneity among studies was tested by Cochran’s Q test with a significance level of 0.10 164 
and quantified by the I2 statistic. An I2 value of 0-25%, 26-50%, 51-75%, or >75% represents no, 165 
low, moderate, or high heterogeneity, respectively. Publication bias was determined by Egger’s 166 
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regression asymmetry test also with a significance level of 0.1 The Duval and Tweedie 167 
nonparametric "trim and fill" method was used to adjust for publication bias if applicable.34  168 
 169 
Stratified analyses were performed to determine modification effects by a few pre-specified 170 
factors, including blood source (cord blood vs. maternal venous blood), outcome diagnosis 171 
(clinician diagnosis vs. parental report), and season variation consideration (yes vs. no). A 172 
random-effects meta-regression model was used to obtain the P value for interaction between 173 
each of these factors and the exposure.35 Sensitivity analyses were conducted to evaluate the 174 
influence of replacing a random-effects model with a fixed-effects model and the influence of a 175 
single study on the associations by omitting one primary study each time in the meta-analysis.  176 
 177 
All analyses were performed by using STATA statistical software (Version 13.0; STATA 178 
Corporation LP, College Station, Texas, USA). A two-sided P value ≤ 0.05 was considered 179 
statistically significant if not otherwise specified. 180 
 181 
RESULTS 182 
Literature search  183 
Fig 1 shows the flow of the study selection process. A total of 130 articles in PubMed and 356 in 184 
EMBASE were identified initially. Of them, 8 in PubMed (5 reviews and 3 case reports) and 102 185 
in EMBASE (28 reviews and 74 case reports) were excluded. Also, 111 in PubMed and 249 in 186 
EMBASE were excluded after reviewing the title and abstract. Of the 11 studies in PubMed and 187 
5 in EMBASE, 3 studies were further excluded after full-text review because of substantial 188 
overlap with other studies. In addition, 4 studies were found via Google Scholar. Thus, by 189 
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systematically searching the literature, 17 studies10,11,24-26,31-33,36-44 were identified. After quality 190 
assessment, one study was excluded.33 Finally, 16 birth cohort studies were included in this 191 
meta-analysis. 192 
 193 
Study characteristics 194 
Characteristics of the 16 included studies are summarized in E Table 2 at the Online Repository. 195 
These primary studies were conducted in Asia,38,40,43 Europe,10,24-26,31,32,36,41,44 North America,42 196 
and Australia.11,37,39 Of the 16 studies, 10 studies focused on asthma, including 8 871 participants 197 
(1 494 incident cases) with an average 5.9-year follow-up; 10 studies reported results on wheeze, 198 
including 9 072 individuals (2 277 incident cases) with an average 5.5-year follow-up; and 10 199 
studies presented findings on respiratory tract infections, including 8 359 individuals (2 562 200 
incident cases) with an average 1.4-year follow-up. The blood 25(OH) D levels were measured 201 
with various methods including chemiluminescence immunoassay (CLIA), 202 
electrochemiluminescence (ECL), enzyme immunoassay (EIA), high-performance liquid 203 
chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS), high-204 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS), and 205 
radioimmunoassay (RIA). The blood samples were either cord blood or maternal venous blood 206 
during pregnancy in different stages. Seven studies were evaluated as high quality,24-26,36,37,40,44 207 
while the other 9 studies as moderate quality.10,11,29,30,38,39,41-43 208 
 209 
Primary analyses 210 
Asthma  211 
According to the available data from 8 studies,10,11,24-26, 37,38,41 a borderline significant inverse 212 
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association between in utero exposure to vitamin D and risk of asthma in offspring was found. 213 
The pooled OR for the offspring’s asthma was 0.84 (95%CI, 0.70 to 1.01; P = 0.064) comparing 214 
the highest to the lowest category of 25 (OH) D levels (Fig 2). No evidence of heterogeneity (I2 = 215 
10.4%, P = 0.349) and publication bias (Egger’s test: P = 0.308) was found.  216 
 217 
No statistically significant linear association was observed based on available data derived from 218 
8 studies.10,24-26,36,37,41,42 The pooled OR for the offspring’s asthma was 0.99 (95%CI, 0.97 to 219 
1.02; P = 0.691) with a 10 nmol/L increment in 25 (OH) D levels. Neither heterogeneity (I2 = 220 
0.0%, P = 0.520) nor publication bias (Egger’s test: P = 0.570) was evidenced.  221 
 222 
Wheeze  223 
Similar to asthma, a borderline significant inverse association was observed between in utero 224 
exposure to vitamin D and risk of wheeze in offspring when combining data from 8 eligible 225 
studies.11, 24-26,31,37,41,44 The pooled OR for wheeze was 0.77 (95%CI, 0.58 to 1.03; P = 0.083) 226 
comparing the highest to the lowest category of 25 (OH) D levels (Fig 3). A moderate 227 
heterogeneity exists across included studies (I2 = 62.1%, P = 0.010). No publication bias was 228 
evident (Egger’s test: P = 0.122).  229 
 230 
No statistically significant linear association was determined using available data from 9 studies. 231 
24-26,31,36,37,39,41,44
 The pooled OR for offspring’s wheeze was 0.98 (95%CI, 0.96 to 1.004; P  = 232 
0.114) with every 10 nmol/L increment in 25 (OH) D levels. No heterogeneity (I2 = 5.3%, P = 233 
0.391) nor publication bias (Egger’s test: P = 0.286) exists.  234 
 235 
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Respiratory tract infections  236 
Ten studies examined cord blood or maternal venous blood25 (OH) D levels in relation to 237 
offspring’s respiratory tract infections.11,24,25,31,32,37,40,41,43,44 The combined results did not reveal a 238 
significant inverse association. The pooled OR was 0.85 (95%CI, 0.66 to 1.09; P = 0.187) as 239 
compared the highest to the lowest category of 25 (OH) D levels (Fig 4). No evidence on 240 
publication bias (Egger’s test: P = 0.486), but a moderate heterogeneity existed across included 241 
studies (I2 = 66.1%, P = 0.003).  242 
 243 
A non-significant linear association was found. The pooled OR was 0.97 (95%CI, 0.94 to 1.01; P 244 
= 0.156) with a 10 nmol/L increment in 25 (OH) D levels. Neither heterogeneity (I2 = 0.0%, P = 245 
0.495) nor publication bias (Egger’s test: P = 0.798) existed. 246 
 247 
Stratified analysis 248 
We examined potential effect modifications of a few pre-specified factors (Table 1). The 249 
association with risk of wheeze was modified by the source of 25 (OH) D (P for interaction = 250 
0.007). A statistically significant inverse association was documented when combining data from 251 
studies with 25(OH) D measured in cord blood. The pooled OR was 0.43 (95%CI, 0.29 to 0.62; 252 
P < 0.001) comparing the highest to the lowest category of cord blood 25(OH) D levels. The risk 253 
of offspring’s wheeze was lowered by 5% with every 10 nmol/L increment in cord blood 25 254 
(OH) D levels (0.95, 95%CI, 0.91 to 0.99; P = 0.009). By contrast, no significant association was 255 
found when combining studies with 25(OH) D measured in maternal venous blood. Other factors 256 
including outcome diagnosis and season variation consideration did not appreciably modify the 257 
associations of interest. Of note, one primary study11 reported sex difference. Hence, we 258 
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requested de novo data on sex difference and received data from 3 primary studies.24-26 After 259 
combining data from these 4 available studies, no significant sex difference was found (data not 260 
shown). 261 
 262 
Sensitivity analysis 263 
When replacing a random-effects model with a fixed-effects model, the results were generally 264 
consistent, except that the association between in utero exposure to 25 (OH) D (highest vs. 265 
lowest) and risk of respiratory tract infection became statistically significant (0.93; 95%CI, 0.91 266 
to 0.95; P < 0.001) (E Table 3 at the Online Repository). Since the most common cause of 267 
recurrent wheezing is asthma attacks, we combined these two endpoints with available data from 268 
10 studies.10,11,24-26,31,37,38,41,44  The pooled OR was 0.80 (95% CI, 0.66 to 0.98; P = 0.028) 269 
comparing the highest to the lowest category of 25 (OH) D levels. 270 
 271 
A couple of studies substantially affect the pooled results (E Table 4 at the Online Repository). 272 
The overall association between 25 (OH) D and asthma was strengthened and became 273 
statistically significant when the study by Camargo and colleagues37 (Categorical analysis: 0.82; 274 
95%CI, 0.67 to 0.999; P = 0.049) or the study by Wills and colleagues26 (Categorical analysis: 275 
0.78; 95%CI, 0.64 to 0.96; P = 0.017) was omitted. Similarly, the overall association between 25 276 
(OH) D and wheeze was strengthened and became statistically significant by omitting the study 277 
by de Jongh and colleagues31 (Categorical association: 0.72; 95%CI, 0.53 to 0.99; P = 0.041) or 278 
by omitting the study by Wills and colleagues26 (Linear association: 0.97; 95%CI, 0.95 to 279 
0.9996; P = 0.047).  280 
 281 
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DISCUSSION 282 
In this meta-analysis, we found that increased in utero exposure to 25(OH) D was inversely 283 
associated with risk of offspring’s wheeze and asthma in childhood, which is in adherence with 284 
the findings from two recent randomized clinical trials of vitamin D supplementation during 285 
pregnancy. The evidence was strengthened when 25 (OH) D levels were measured in cord blood. 286 
The observed associations were not appreciably modified by sex, outcome diagnosis methods, 287 
and season variation consideration in primary studies. 288 
 289 
Strengths and limitations 290 
One unique strength of this meta-analysis is that we obtained de novo data from a few primary 291 
studies,24-26 which provides more accurate and/or additional information specifically for this 292 
meta-analysis. Another main strength of this study is that in utero exposure to vitamin D is 293 
measured by objective biomarkers (i.e., cord blood or maternal venous blood) that is a reflection 294 
of the current circulating vitamin D obtained from diet and sun exposure. However, we realize that 295 
serum 25 (OH) D may not be the best biomarker, alternative vitamin D biomarkers (e.g., tissues 296 
and intracellular fluid) are definitely needed in future studies depending on the scale of the study 297 
and the budget and ethical considerations. 298 
 299 
Despite the above merits, the results should be interpreted with caution because of some 300 
limitations. First, moderate heterogeneity existed in some pooled analyses. The variations of 301 
several factors may generate the heterogeneity. For example, different study population, study 302 
location, sample size, duration of follow-up, source of blood samples for measuring vitamin D 303 
status, outcome diagnosis, season variation consideration, and adjustment for different covariates 304 
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in primary studies. In the analyses, a random-effects model was used in concordance with the 305 
heterogeneity. In addition, stratified analyses were conducted to explore any potential effect 306 
modifier. Second, asthma and respiratory tract infections in some primary studies and wheeze in 307 
all the studies were reported by parents except the COPSAC study where wheeze was diagnosed 308 
at acute visits to the research clinic and by a daily diary of respiratory symptoms. Although the 309 
signs of these health conditions may be clearly visible, the likelihood of misclassification could 310 
not be completely ruled out, e. g., parents might report wheeze as respiratory tract infection. 311 
Nevertheless, the potential misclassification should not substantially affect our results since the 312 
great majority of the parental reports were based on clinician’s diagnosis. Third, maternal 313 
25(OH) D levels in some studies were measured in venous blood during pregnancy at different 314 
time points. This inconsistency of the measurement time window might introduce errors in the 315 
exposure assessment, but this would presumably lead to a bias towards the null. However, most 316 
of the studies (12 out of 16) measured 25 (OD) D in the later stage of pregnancy (i.e., 2 studies at 317 
34-week gestation) or at birth (10 studies). Thus, the different measurement timing in a few 318 
studies should not substantially bias our findings. Fourth, most of the primary studies measured 319 
25 (OH) D levels only once, which might not adequately reflect the long-term exposure and may 320 
attenuate any possible associations of interest because of random variation. Our findings are 321 
more likely to suggest a beneficial effect of higher levels of vitamin D in late pregnancy.  Further 322 
longitudinal studies with repeat measurements in 25 (OH) D levels at different stages of 323 
pregnancy are warranted. Fifth, the baseline vitamin D levels varied across studies, but we were 324 
not able to adjust for this variation in the meta-analysis due to lack of original data. Sixth, we 325 
were not able to pool the data comparing individuals with vitamin D levels ≥75 nmol/L vs. 326 
everyone else due to data insufficiency.  Finally, although the pooled analyses were based on 327 
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fully adjusted models in the individual studies, our results might be biased by the inherent 328 
limitations in the primary studies such as residual confounding or confounding from unknown or 329 
unmeasured factors. 330 
 331 
Comparison to previous studies  332 
In light of the considerable complexity of the pathogenesis of these respiratory outcomes, it is 333 
not surprising to see the inconsistency in the available data on vitamin D status and the 334 
offspring’s asthma, wheeze and respiratory tract infections. One meta-analysis nested in a 335 
systematic review based only on 3 birth cohort studies suggested a possible association between 336 
low serum vitamin D levels and risk of asthma in children.21 Another review, which summarized 337 
data from 9 cross-sectional, 2 case-control, and 12 cohort studies in both children and adults, 338 
suggested that higher serum levels of 25 (OH) D were related to lower risk of asthma 339 
exacerbations. However, the study did not provide information on the association of in utero 340 
exposure to 25 (OH) D with the development of asthma in childhood.22 Notably, neither of these 341 
two reviews considered wheeze and respiratory tract infections as outcomes. In addition, one 342 
recent meta-analysis combined data from 4 cohort studies found that maternal dietary intake of 343 
vitamin D was associated with lower odds of offspring’s wheeze during childhood.45 However, 344 
dietary intake only accounts for 10% of circulating 25 (OH) D. Findings from the present meta-345 
analysis are generally consistent with that of the previous reviews and provide important 346 
additional information on in utero exposure to 25 (OH) D and risk of the offspring’s wheeze and 347 
respiratory tract infections in childhood. Furthermore, the findings are in line with two recently 348 
published randomized clinical trials of vitamin D supplementation during pregnancy showing a 349 
non-significant more than 20 % reduced risk of persistent wheeze/asthma at age 0-3 years.19,20  350 
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Of note, a recent randomized clinical trial found that the maternal or cord blood vitamin D levels 351 
should be at least 75 nmol/L in order to result in reversal or protection of the autoimmune effects. 352 
20
, but the optimal level during pregnancy for lung and immune maturation is still unknown. In 353 
our meta-analysis, the distribution of 25 (OH) D levels varied across the primary studies, but 354 
overall approximately 28% participants had 25 (OH) D levels ≥ 75 nmol/L (E Table 5 at the 355 
Online Repository). Thus, the pooled results are biologically in concordance with findings from 356 
the randomized clinical trials. 357 
   358 
Possible explanations 359 
Vitamin D is an immune-regulator, involved in both cellular immunity and humeral immunity.46 360 
There are several explanations for the potential beneficial effect of vitamin D on the 361 
development of asthma and wheeze, including: 1) 25 (OH) D can modify T-cell differentiation 362 
and dendritic cell activation,17 which plays an important role in the inflammatory response; 2) 25 363 
(OH) D can induce a shift in the profile of cytokine secretion during an immune response to an 364 
anti-inflammatory phenotype, with regulatory T lymphocytes predominating in the cell 365 
population;47 and 3) In macrophages, vitamin D can promote antimicrobial responses through the 366 
induction of antibacterial proteins,18 and stimulation of autophagy and autophagosome activity.   367 
 368 
One study demonstrated a very high correlation between maternal and umbilical cord blood 369 
vitamin D levels (Spearman’s correlation = 0.91),48 which supports a common belief that 25 370 
(OH) D measured in maternal venous blood should be parallel to the measures in cord blood. 371 
However, we found that the association was more pronounced in the studies that 25 (OH) D was 372 
measured in cord blood. Notably, the heterogeneity of the time window for measuring 25 (OH) D 373 
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levels in maternal venous blood during pregnancy may attenuate any possible associations.  374 
 375 
Studies suggest that early lung development differs between boys and girls,49,50 which may 376 
explain the higher prevalence of asthma in boys than that of girls before puberty.51 Although the 377 
present meta-analysis did not observe sex difference, a potential effect modification of sex 378 
cannot be completely ruled out because the available data were derived from limited number of 379 
studies.11,24-26  380 
 381 
Because of seasonal variations in ultraviolet radiation exposure, seasonal variation in vitamin D 382 
status is recognized.52 One study found that vitamin D deficiency was marginally associated with 383 
an increased risk of lower respiratory tract infections in children born in fall, but not in children 384 
born in other three seasons.32 Some, but not all primary studies considered vitamin D seasonal 385 
variation in the analysis. This inconsistency may affect the pooled results and/or contribute to the 386 
heterogeneity. Nevertheless, seasonal variation consideration did not materially modify the 387 
associations of interest in this meta-analysis.  388 
 389 
CONCLUSION 390 
In conclusion, this meta-analysis of birth cohort studies accumulates evidence supporting that 391 
increased in utero exposure to 25(OH) D is inversely associated with the risk of asthma and 392 
wheeze during childhood. These findings are in keeping with the results of two recently 393 
published randomized clinical trials of vitamin D supplementation during pregnancy showing a 394 
more than 20% reduced risk of persistent wheeze/asthma at age 3 years.   395 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
ACKNOWLEDGEMENTS 396 
Author contribution: H. Feng, P. Xun, Y. Wan, and K. He contributed to concept and design of 397 
the study; H. Feng and P. Xun developed the search strategy, performed the literature review, 398 
data extraction, and study quality assessment; P. Xun designed and conducted the data analysis 399 
and interpretation; P. Xun contacted the authors of primary studies for additional information; K. 400 
Pike, A. Wills, B. Chawes, and H. Bisggard provided de novo data specifically for this meta-401 
analysis; P. Xun and H. Feng contributed to tables and figures. H. Feng, P. Xun, Y. Wan, and K. 402 
He drafted the manuscript; P. Xun and K. He had full access to all the data in this meta-analysis; 403 
and all the authors contributed to the manuscript revision, reviewed and approved the final 404 
manuscript. H. Feng and P. Xun contributed equally. 405 
 406 
Disclosure of potential conflict of interest:  H. Bisgaard reports personal fees from Chiesi, outside 407 
the submitted work; other authors have no relevant interests to declare.   408 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
FIGURE LEGENDS 409 
Fig 1. Flowchart of study selection 410 
Fig 2. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of asthma. The summary 411 
estimates (diamond data markers) were obtained by using a random-effects model. The dots 412 
indicate the adjusted ORs comparing the highest to lowest category of, or per 10 nmol/L 413 
increment in 25(OH) D levels. The size of the shaded square is proportional to the weight of each 414 
study. CI: confidence interval; OR: odds ratio. 415 
 416 
Fig 3. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of wheeze. The summary 417 
estimates (diamond data markers) were obtained by using a random-effects model. The dots 418 
indicate the adjusted ORs comparing the highest to lowest category of, or per 10 nmol/L 419 
increment in 25(OH) D levels. The size of the shaded square is proportional to the weight of each 420 
study. CI: confidence interval; OR: odds ratio. 421 
 422 
Fig 4. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of respiratory tract infections. 423 
The summary estimates (diamond data markers) were obtained by using a random-effects model. 424 
The dots indicate the adjusted ORs comparing the highest to lowest category of, or per 10 425 
nmol/L increment in 25(OH) D levels. The size of the shaded square is proportional to the 426 
weight of each study. CI: confidence interval; OR: odds ratio; RTI: respiratory tract infection. 427 
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TABLE 1. Stratified analyses of the associations between in utero exposure to 25 (OH) D and risk of childhood asthma, wheeze and respiratory tract 
infections 
Outcome 25(OH) D Potential modifiers No. of cohorts No. of  
participants / events 
Heterogeneity  
test 
OR  
(95%CI) 
P  
for interaction 
Asthma Highest vs. lowest Overall 8 8 438/1 446 I2 =  10.4%, P = 0.349 0.84 (0.70 to1.01) -- 
 Blood source Cord blood 3 1 208/238 I2 = 33.3%, P = 0.223 0.73 (0.39 to 1.37) 0.760 
Maternal venous blood 5 7 230/1 208 I2 = 15.2%, P = 0.318 0.85 (0.70 to 1.04) 
Outcome  
assessment 
Doctor diagnosed 4 1 533/144 I2 = 13.3%, P = 0.326 0.71 (0.46 to 1.09) 0.435 
Parent-report 4 6 905/1 302 I2 = 17.8%, P = 0.302 0.88 (0.71 to 1.08) 
Season  
Considered* 
Yes 4 5 870/1 080 I2 = 21.1%, P = 0.284 0.87 (0.67 to 1.11) 0.684 
 No 4 2 567/366 I2 = 22.1%, P = 0.278 0.78 (0.56 to 1.10) 
↑ Per 10 nmol/L Overall 8 8 397/1 468 I2 = 0.0%, P = 0.520 0.99 (0.97 to 1.02) -- 
 Blood source Cord blood 4 1 455/260 I2 = 0.0%, P = 0.736 1.04 (0.98 to 1.10) 0.137 
Maternal venous blood 4 6 942/1208 I2 = 0.0%, P = 0.582 0.98 (0.96 to 1.01) 
Outcome 
 assessment 
Doctor diagnosed 3 1 253/147 I2 = 15.8%, P = 0.305 1.01 (0.93 to 1.09) 0.810 
Parent-report 5 7 144/1321 I2 = 0.0%, P = 0.439 0.99 (0.97 to 1.01) 
Season  
Considered* 
Yes 6 6 304/1 128 I2 = 11.1%, P = 0.345 1.00 (0.97 to 1.03) 0.532 
No 2 2 093/340 I2 = 0.0%, P = 0.757 0.97 (0.91 to 1.04) 
Wheeze† Highest vs. lowest Overall 8 8 694/2 150 I2 = 62.1%, P = 0.010 0.77 (0.58 to 1.03) -- 
  Blood source Cord blood 3 1 240/612 I2 = 0.0%, P = 0.757 0.43 (0.29 to 0.62) 0.007 
 Maternal venous blood 5 7 454/1 538 I2 = 0.0%, P = 0.825 1.00 (0.83 to 1.20) 
 Season  
Considered* 
Yes 3 4 263/920 I2 = 83.2%, P = 0.003 0.60 (0.29 to 1.23) 0.427 
 No 5 4 431/1 230 I2 = 28.8%, P = 0.230 0.89 (0.67 to 1.18) 
 ↑ Per 10 nmol/L Overall  9 8 784/2 277 I2 = 5.3%, P = 0.391 0.98(0.96 to 1.004) -- 
  Blood source Cord blood 5 1 618/665 I2 = 0.0%, P = 0.438 0.95 (0.91 to 0.99) 0.074 
 Maternal venous blood 4 7 166/1 538 I2 = 0.0%, P = 0.962 1.00 (0.97 to 1.02) 
 Season  
Considered* 
Yes 5 4 641/973 I2 = 28.0%, P = 0.235 0.97 (0.94 to 1.01) 0.512 
 No 4 4 143/1 230 I2 = 0.0%, P = 0.485 1.00 (0.96 to 1.03) 
RTIs Highest vs. lowest Overall  9 7 129/2 365 I2 = 66.1%, P = 0.003 0.85 (0.66 to 1.09) -- 
  Blood source Cord blood 6 2 753/1 250 I2 = 59.8%, P = 0.029 0.74(0.53 to 1.02) 0.227 
 Maternal venous blood 3 4 426/1 115 I2 = 81.8%, P = 0.004 1.16 (0.58 to 2.30) 
 Outcome  
assessment 
Doctor diagnosed 6 5 280/1 644 I2 = 66.4%, P = 0.011 0.81 (0.61 to 1.07) 0.653 
 Parent-report 3 1 899/721 I2 = 77.0%, P = 0.013 0.95 (0.45 to 2.03) 
 Season  
Considered* 
Yes 5 3 246/1 232 I2 = 73.4%, P = 0.005 0.72 (0.41 to 1.27) 0.471 
 No 4 3 933/1 133 I2 = 58.5%, P = 0.065 0.91 (0.70 to 1.17) 
 ↑ Per 10 nmol/L Overall  9 8,153/2,500 I2 = 0.0%, P = 0.495 0.97 (0.94 to 1.01) -- 
  Blood source Cord blood 5 2 547/1 188 I2 = 0.0%, P = 0.892 0.95 (0.87 to 1.03) 0.515 
 Maternal venous blood 4 5 606/1 312 I2 = 48.0%, P = 0.123 0.98 (0.92 to 1.04) 
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 Outcome  
assessment 
Doctor diagnosed 4 3 199/1 200 I2 = 0.0%, P = 0.878 0.94 (0.89 to 0.99) 0.120 
 Parent-report 5 4 954/1 300 I2 = 0.0%, P = 0.466 1.01 (0.95 to 1.06) 
 Season  
Considered* 
Yes 6 4 426/1 429 I2 = 0.0%, P = 0.541 0.99 (0.94 to 1.04) 0.811 
 No 3 3 727/1 071 I2 = 20.3%, P = 0.285 0.96 (0.89 to 1.04) 
25(OH) D, 25-Hydroxyvitamin D; CI, confidence interval; RTI, lower respiratory tract infection; OR, odds ratio.  
*Season of measurement of the exposure was adjusted in the model or season-standardized exposure was used. 
†Wheeze, as a symptom, was parental report in all the included studies except the COPSAC study where wheeze was diagnosed at acute visits to the research clinic and by a daily 
diary of respiratory symptoms. 
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111 Excluded after abstract review from PubMed 
       60 Not associated with asthma or wheeze or respiratory 
infections 
       39 Maternal Vitamin D not available 
     2 Maternal Vitamin D not tested from blood sample 
   10 case control studies 
249 Excluded after abstract review from EMBASE 
       170 Not associated with asthma or wheeze or 
respiratory infections 
         40 Maternal Vitamin D not available 
           6 Maternal Vitamin D not tested from blood sample 
         33 Case-control studies 
 
130 and 356 related studies identified from PubMed and EMBASE, respectively 
 
    8 Excluded from PubMed 
       5 Reviews  
       3 Case reports 
102 Excluded from EMBASE 
       28 Reviews 
       74 Case reports 
 
122 studies retrieved for abstract review from PubMed and 254 from EMBASE  
11 studies identified for full-text review from PubMed and 5 from EMBASE 
 3 Overlapped studies from two databases were excluded 
13 studies identified after full review in sum 
4 Added from the reference list 
(Other new associated articles can’t be located through the 
Google Scholar search) 
   
16 studies included in the main meta-analysis; one was only included in the sensitivity analysis 
due to low quality 
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Asthma (Highest vs. Lowest)
 Camargo et al, 201137
Morales et al, 201241
Pike et al, 201225
Magnus et al, 201310 
Wills et al, 201326
Chawes et al, 201424 
Zosky et al, 201411 
Chiu et al, 201538
Heterogeneity (I2 = 10.4%, P = 0.349) 
Asthma (↑ Per 10 nmol/L)
 Camargo et al, 201137 
Rothers et al, 201142
Morales et al, 201241
Pike et al, 201225
Magnus et al, 201310 
Wills et al, 201326
Baïz et al, 201436 
Chawes et al, 201424 
Heterogeneity (I2 = 0.0%, P = 0.520) 
Study 
1.06 (0.60 to 1.87) 
0.89 (0.60 to 1.33) 
1.04 (0.60 to 1.80) 
0.67 (0.48 to 0.94) 
1.00 (0.75 to 1.33) 
0.61 (0.11 to 3.48) 
0.55 (0.24 to 1.26) 
0.44 (0.19 to 1.02) 
0.84 (0.70 to 1.01) 
1.03 (0.97 to 1.10) 
1.13 (0.95 to 1.35) 
0.95 (0.80 to 1.13) 
0.98 (0.91 to 1.05) 
0.95 (0.90 to 1.01) 
1.00 (0.96 to 1.04) 
1.06 (0.82 to 1.35) 
1.00 (0.84 to 1.19) 
0.99 (0.97 to 1.02) 
OR (95%CI)
9.53
17.38
10.04
22.86
30.01
1.09
4.59
4.50
100.00
16.10
2.12
2.17
11.45
19.17
45.84
1.04
2.11
100.00
Weight, %
  
0.25 0.5 1.0 2.0 4.0 
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Wheeze (Highest vs. Lowest)
 Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Wills et al, 201326
Chawes et al, 201424
de Jongh et al, 201431 
Zosky et al, 201411 
Stelmach et al, 201544 
Heterogeneity (I2 = 62.1%, P = 0.010) 
Wheeze (↑ Per 10 nmol/L)
 
Camargo et al, 201137 
Morales et al, 201241
Pike et al, 201225 
Wills et al, 201326
Baïz et al, 201436 
Chawes et al, 201424 
de Jongh et al, 201431 
Jones et al, 201539
Stelmach et al, 201544 
Heterogeneity (I2 = 5.3%, P = 0.391) 
Study 
0.47 (0.30 to 0.72) 
0.94 (0.62 to 1.43) 
0.94 (0.66 to 1.33) 
1.06 (0.78 to 1.44) 
0.32 (0.11 to 0.95) 
1.25 (0.72 to 2.15) 
0.76 (0.37 to 1.59) 
0.36 (0.14 to 0.89) 
0.77 (0.58 to 1.03) 
0.95 (0.91 to 0.99) 
0.97 (0.88 to 1.07) 
1.00 (0.96 to 1.05) 
1.00 (0.97 to 1.02) 
1.12 (0.82 to 1.52) 
0.90 (0.78 to 1.04) 
1.00 (0.90 to 1.11) 
0.95 (0.77 to 1.18) 
0.00 (0.00 to 8.55) 
0.98 (0.96 to 1.00) 
OR (95%CI)
 
14.98
15.41
12.64
9.26
7.05
100.00
22.25
4.79
19.82
45.35
0.48
2.15
4.17
0.98
0.00
100.00
Weight, %
16.95
18.12
5.59
0.25 0.5 1.0 2.0 4.0 
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RTIs (Highest vs. Lowest) 
 Camargo et al, 201137 
Morales et al, 201241
Pike et al, 201225
Mohamed et al, 201340 
Shin et al, 201343 
Chawes et al, 201424 
de Jongh et al, 201431 
Luczynska et al, 201432 
Stelmach et al, 201544
Heterogeneity (I2 = 66.1%, P = 
0.003) 
RTIs (↑ Per 10 nmol/L) 
 
Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Magnus et al, 201310 
Shin et al, 201343 
Chawes et al, 201433 
de Jongh et al, 201431 
Luczynska et al, 201432 
Stelmach et al, 201544 
Heterogeneity (I2 = 0.0%, P = 0.495) 
Study 
0.49 (0.27 to 0.88)
0.67 (0.50 to 0.90)
1.68 (0.94 to 2.99)
0.93 (0.91 to 0.95) 
0.28 (0.12 to 0.66)
0.78 (0.34 to 1.81)
1.58 (0.80 to 3.14)
0.89 (0.54 to 1.47)
1.05 (0.51 to 2.17)
0.85 (0.66 to 1.09) 
0.90 (0.74 to 1.09) 
0.93 (0.87 to 0.99) 
1.03 (0.96 to 1.11) 
0.93 (0.81 to 1.07) 
0.90 (0.71 to 1.13) 
0.98 (0.86 to 1.11) 
1.03 (0.92 to 1.15) 
0.95 (0.78 to 1.16) 
5.34 (0.01 to 2360.83) 
0.97 (0.94 to 1.01) 
OR (95%CI)
9.96
17.08
10.21
22.35
6.20
6.31
8.36
11.79 
7.75
100.00
3.80 
33.09
29.20
7.69
2.59 
9.00
10.94
3.70
0.00
100.00
Weight, % 
0.25 0.5 1.0 2.0 4.0 
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E Table 1. Quality assessment using Newcastle-Ottawa quality assessment scale for the studies included in the 
meta-analysis  
Source Selection* Comparability† Outcome‡ Quality 
Gale et al., 
2008, the UK28 
★★★ zero ★ low 
Camargo et al., The New Zealand Asthma  
and  Allergy Cohort Study, 2011, New Zealand37 
★★★★ ★★ ★★ high 
Rothers et al., The Tucson Infant Immune Study, 
2011, USA42 
★★★ ★★ ★ moderate 
Morales et al., The INMA Study, 2012, Spain41 ★★★★ ★★ ★ moderate 
Pike et al, The Southampton Women’s Study, 
2012, the UK25 
★★★★ ★★ ★ High 
Magnus et al, The Norwegian Mother and Child  
Cohort Study,  2013, Norway10  
★★★ ★★ ★ Moderate 
Mohamed et al., 2013, Saudi Arabia40 ★★★★ ★★ ★★ High 
Shin et al., the COCOA Study, 2013, Korea43 ★★★ ★★ ★★ Moderate 
Wills et al., The Avon Longitudinal Study of  
Parents and Children, 2013, the UK26 
★★★★ ★★ ★★ High 
Baïz  et al., The EDEN Cohort Study, 2014, France36 ★★★★ ★★ ★★ High 
Chawes et al., The COPSAC2000 Birth Cohort Study, 
2014, Denmark24 
★★★ ★★ ★★★      High 
de Jongh et al., The Southampton Women’s Survey, 
2014, the UK31 
★★★ ★★ ★★ Moderate 
Luczynska et al., 2014, Germany32 ★★★ ★★ ★★ Moderate 
Zosky  et al., The Western Australian Pregnancy  
Cohort Study, 2014, Australia11 
★★★ ★★ ★ Moderate 
Chiu et al., The PATCH study, 2015,Taiwan38 ★★ ★★ ★★ Moderate 
Jones et al., 2015,  Australia39 ★★★ ★ ★★ Moderate 
Stelmach et al., The Polish Mother and Child Cohort 
Study, 2015, Poland44 
★★★★ ★★ ★★ High 
25(OH) D, 25-Hydroxyvitamin D; COCOA, the COhort for Childhood Origin Asthma and allergic disease; COPSAC, Copenhagen 
Prospective Study on Asthma in Childhood; EDEN, Étude sur les Déterminants pré-et postnatals précoces du développement 
psychomoteur et de la santé de l’ENfant (Pre- and postnatal determinants of child growth, development and health); INMA, the 
INfancia y Medio Ambiente (Environment and Childhood); PATCH, birth cohort in the Prediction of Allergies in Taiwanese Children;  
UK, United Kingdom; USA, the United States of America.  
*Stars awarded for representativeness of the birth cohort, selection of the normal birth cohort, the accuracy of vitamin D test and the 
ascertainment of the diagnostic of the asthma.  A maximum of 4 stars is to be awarded.  
†Stars awarded for adjustment of related confounders. A maximum of 2 stars is to be awarded.  
‡Stars awarded for assessment of asthma, length of follow-up, and adequacy of follow-up cohorts. A maximum of 3 stars is to be 
awarded.  
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E Table 2. Characteristics of 16 included studies in this meta-analysis 
Source Proportion 
of boys, % 
Follow-up 
time 
No. of 
individuals
/events 
Exposure 
categories 
Exposure 
assessment 
Outcome and 
its assessment Adjusted variables Main results 
Camargo et al.,  
The New Zealand 
Asthma and 
Allergy Cohort 
Study,  
2011, New 
Zealand37 
50.5 Asthma: 
5 years 
 
Wheeze: 
5 years 
 
Respiratory 
infection: 
3 months 
 Asthma: 
 823/181 
 
 Wheeze: 
 823/533 
 
Respiratory   
infection: 
 882/553 
 
Categories of 
25(OH) D 
(nmol/L): 
  <25; 
  25-74; 
  ≥75. 
 
 
 
 
Time: at birth. 
 
Method: 
The Diasorin 
(Stillwater, MN) 
LIAISON automated 
CLIA. 
 
Blood sample: 
the newborn’s cord 
blood. 
 
 
Asthma was 
defined as parent 
report of doctor-
diagnosed asthma 
by the time the 
child was 5 years 
old and reported 
inhaler use or 
wheezing since the 
age of 4 years old. 
 
Parent report 
wheeze status was 
cumulatively 
assessed at age 15 
months, 3 years 
and 5 years by 
using the same 
question across all 
visits: “Has he/she 
ever had wheezing 
or whistling in the 
chest at any 
time? ” 
 
Respiratory 
infection was 
defined as 
a parents’ positive 
response to a series 
of questions (“Has 
[child’s name] had 
any of the 
Asthma: 
Season of birth plus 
13 potential 
confounders (study 
site, maternal age at 
birth, New Zealand 
deprivation index, 
maternal history of 
asthma, paternal 
history of asthma, 
gestational age, 
child’s sex, child’s 
ethnicity, any 
smoking during 
pregnancy, any 
passive smoke 
exposure at 3 months 
of age, number of 
children younger than 
16 years in household 
at the time the child 
was 3 months old, 
endotoxin on bedroom 
floor at the time the 
child was 3 months 
old, and duration of 
exclusive 
breastfeeding). 
 
Wheeze: 
The confounders 
above. 
 
Incident asthma by age 5 
[OR(95%CI]*#:   
   0.94 (0.53 to 1.64);  
   1.19 (0.78 to1.83);  
   1.00 (reference). 
Per 10 nmol/L increment 
[OR(95%CI)]:  
  1.03 (0.97 to1.10). 
 
Wheeze by age 5  
[OR(95%CI]*: 
  2.15 (1.39 to 3.33);  
  1.63 (1.17 to 2.26);  
  1.00 (reference). 
Per 10 nmol/L increment 
[OR(95%CI)]:  
  0.95 (0.91 to 0.99). 
 
Respiratory infection 
by age 3 months  
[OR(95%CI]: 
  2.04 (1.13 to 3.67);  
  1.35 (0.88 to 2.08);  
  1.00 (reference). 
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following?”) about 
colds, cough, whoo
ping cough, chest 
infections, and 
ear infections 
during the first 3 
months of life.  
 
Respiratory infection: 
The confounders 
above plus damp 
musty smell in any 
room of home at the 
time the child was 3 
months old. 
Rothers et al.,  
The Tucson Infant 
Immune Study,  
2011, USA42 
48.9 Asthma: 
5 years 
194/29 Categories of 
25(OH) D 
(nmol/L) 
  < 50; 
  50-74.9;  
  75-99.9; 
   ≥ 100. 
Time: at birth. 
 
Method: LC-MS. 
 
Blood sample: 
the newborn’s cord 
blood. 
 
Doctor diagnosed 
asthma at 1, 2, 3, 
or 5 years plus 
either asthma 
symptoms or 
medication use 
since 4 y of age. 
 
Maternal ethnicity, 
household smoking, 
and birth season. 
Prevalent asthma at year 5  
[OR(95%CI)]: 
  0.5 (0.2 to 1.6); 
  1.0 (reference); 
  1.1 (0.4 to 3.1); 
  1.4 (0.4 to 5.4). 
Morales et al.,  
The INMA Study, 
2012, Spain41 
 
 
 
51.0 Asthma: 
4-6 years 
 
Wheeze: 
4 years 
 
  LRTI: 
  1 year 
 
 
 
Asthma: 
1 233/253 
 
 Wheeze: 
 1 223/220 
 
 LRTI: 
1 693/627 
 
Quartiles of 
25(OH) D 
(ng/ml): 
  <21.9; 
  21.9-29.1; 
  29.2-37.0; 
  ≥37.1. 
 
 
Time: 77% were 
done during the 
second trimester 
of pregnancy, with 
22% during the 
1st trimester and 1% 
late in pregnancy. 
 
Method: HPLC. 
 
Blood sample:  
the mother’s plasma. 
Asthma was 
defined as parental 
report of doctor-
diagnosed asthma 
or receiving 
treatment at the 
age of 4-6 years or 
wheezing since the 
age of 4 years. 
 
Wheezing was 
defined as parent 
reported history of 
wheezing at the 
age of 1 year and 
annually thereafter. 
 
Diagnosis of LRTI 
was physician 
confirmed. 
 
Asthma/wheeze/ 
LRTI: Child’s sex, 
maternal education, 
siblings at birth, 
breastfeeding 
duration, maternal 
smoking in 
pregnancy, day-care 
attendance, maternal 
asthma, and maternal 
pre-pregnancy BMI. 
 
Asthma at age 4-6 
[OR(95%CI)]: 
  Q1:1.00 (reference); 
  Q2:0.88 (0.59 to 1.29); 
  Q3:0.81 (0.54 to 1.20); 
  Q4:0.89 (0.59 to 1.32). 
 
Wheezing at age 4  
[OR(95%CI)]: 
  Q1:1.00 (reference); 
  Q2:0.89 (0.59 to 1.34); 
  Q3:0.82 (0.54 to 1.25); 
  Q4:0.94 (0.62 to 1.43). 
 
LRTI at age 1  
[OR (95%CI)]: 
  Q1:1.00 (reference); 
  Q2:0.89 (0.67 to 1.19); 
  Q3:0.92 (0.70 to 1.23); 
  Q4:0.67 (0.50 to 0.90). 
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Pike et al.,  
The Southampton 
Women’s Study, 
2012, the UK25† 
51.7 Asthma: 
6 years 
 
Wheeze: 
6 years 
 
LRTI: 
6 months 
 
 
Asthma: 
860/87 
 
Wheeze: 
856/504 
 
LRTI: 
858/106 
Tertiles of 
25(OH) D 
(nmol/L):  
  10.4~46; 
  46.1~74; 
  74~203. 
 
Time: at 34 weeks’ 
gestation. 
 
Method: RIA 
(DiaSorin, 
Stillwater, 
Minnesota, USA, 
coefficient of 
variability<10%). 
 
Blood sample:  
the mother’s serum. 
Asthma was 
diagnosed by 
doctor and defined 
as current based 
upon symptoms or 
asthma treatment 
present within the 
last 12 months. 
 
Wheeze: 
Mothers were 
asked at each visit 
whether their child 
had experienced 
‘episodes of 
chestiness 
associated with 
wheezing or 
whistling in his/her 
chest since they 
were last seen in 
the study’. 
 
LRTI was defined 
as parent 
answering yes to 
either ‘chest 
infection or 
bronchitis’, or 
‘bronchiolitis or 
pneumonia’ in first 
6 months. 
Asthma: 
Maternal education, 
maternal asthma, 
paternal asthma, and 
paternal rhinitis. 
 
Wheeze: 
Maternal BMI, child’s 
sex, maternal 
education, maternal 
asthma, paternal 
asthma, and maternal 
rhinitis. 
 
LRTI: 
Parity, maternal 
smoking in 
pregnancy, year of 
birth, and season of 
birth. 
 
Asthma at age 6  
[OR(95%CI)]: 
All: 
  T1:1.00 (reference); 
  T2:0.70 (0.39 to 1.28); 
  T3:1.04 (0.60 to 1.80). 
Boys: 
  T1:1.00 (reference); 
  T2:1.09 (0.51 to 2.34); 
  T3:1.24 (0.58 to 2.67). 
Girls: 
  T1:1.00 (reference); 
  T2:0.30 (0.10 to 0.88); 
  T3:0.88 (0.39 to 1.97). 
 
Per 10 nmol/L increment 
[OR(95%CI)]:  
All: 0.98 (0.92 to 1.04). 
Boys: 1.00 (0.90 to 1.10). 
Girls: 0.96 (0.86 to 1.08). 
 
Any wheeze at or before 6 
years old [OR(95%CI)]: 
All : 
  T1:1.00 (reference); 
  T2:0.85 (0.60 to 1.21); 
  T3:0.94 (0.66 to 1.33). 
Boys: 
  T1:1.00 (reference); 
  T2:1.22 (0.71 to 1.83); 
  T3:1.04 (0.63 to 1.71). 
Girls: 
  T1:1.00 (reference); 
  T2:0.59 (0.36 to 0.97); 
  T3:0.79 (0.48 to 1.31). 
 
Per 10 nmol/L increment 
[OR(95%CI)]:  
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All: 1.00 (0.96 to 1.05). 
Boys: 1.01 (0.95 to 1.08). 
Girls: 0.98 (0.92 to 1.05).  
 
LRTI before 6 months old 
[OR(95%CI)]: 
All: 
  T1:1.00 (reference); 
  T2:1.05 (0.57 to 1.93); 
  T3:1.68 (0.95 to 2.99). 
Boys: 
  T1:1.00 (reference); 
  T2:0.90 (0.42 to 1.96); 
  T3:1.35 (0.65 to 2.81). 
Girls: 
  T1:1.00 (reference); 
  T2:1.63 (0.56 to 4.69); 
  T3:3.33 (1.17 to 9.26). 
 
 
Per 10 nmol/L increment 
[OR(95%CI)]: 
All: 1.03 (0.96 to 1.11). 
Boys: 1.01 (0.93 to 1.11). 
Girls: 1.08(0.97 to 1.21). 
 
Magnus et al., 
The Norwegian 
Mother and Child 
Cohort Study,  
2013, Norway10  
NA Asthma: 
3 years 
 
LRTI: 
3 years 
Asthma: 
1 672/489 
 
LRTI: 
1 180/297 
 
Categories of 
25(OH) D 
(nmol/L):  
  ≤50; 
  51-75; 
  >75. 
 
 
Time: median 
gestational week of 
sample collection 
was 18 weeks 
(range: 9, 35). 
 
Method: HPLC-MS. 
 
Blood sample: 
the mother’s plasma. 
 
The definition of 
asthma is based on 
meeting both 
criteria: (i) the 
mother responding 
yes, has now to 
whether the child 
had asthma on the 
36-month 
questionnaire, and 
(ii) the mother 
reporting names of 
Asthma and LRTI: 
Maternal age at 
delivery, maternal 
education, maternal 
parity, region of 
delivery, maternal 
pre-pregnancy BMI, 
maternal smoking 
during pregnancy, 
maternal 
midpregnancy plasma 
folate level, maternal 
Asthma at age 5  
[OR(95%CI]: 
  1.00 (reference); 
  0.84 (0.61 to 1.17); 
  0.67 (0.48 to 0.95). 
Per 20 nmol/L increment 
[OR(95%CI)]: 
  0.91 (0.81 to 1.02). 
 
Per 20 nmol/L increment 
in 25(OH) D with 
frequency of LRTIs at age 
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inhaled asthma 
medications. 
 
LRTI: 
Mother reported.  
history of asthma, 
maternal multivitamin 
use during pregnancy, 
maternal frequency of 
leisure time physical 
activity during 
pregnancy, gestational 
week of sample and 
season of sample 
collection. 
   
3 [OR(95%CI]: 
  None: 1.00 (reference); 
  1 or 2: 0.98 (0.87 to 
1.12); 
   ≥3: 0.74 (0.58 to 0.93). 
 
 
 
 
Mohamed et al.,  
2013, Saudi 
Arabia40 
59.2 Acute 
LRTI: 
2 years 
Acute 
LRTI: 
206/62 
Categories of 
 25(OH) D 
(nmol/L):  
 ≤50; 
  >50. 
 
Time: At birth. 
 
Method: RIA 
(Immunodiagnostic 
systems Inc., 
Fountain Hills, 
AZ, USA). 
 
Blood sample: 
the newborn’s cord 
blood. 
LRTI: clinical 
diagnostic of 
bronchiolitis or 
pneumonia based 
on medical record 
review. 
Birth weight, maternal 
age, maternal asthma, 
and skin color. 
Acute LRTI at age 
2[OR(95%CI)]: 
  1.08 (1.05 to 1.10); 
  1.00 (reference). 
 
 
Shin et al.,  
the COCOA Study, 
2013, Korea43 
54.1 Respiratory 
tract 
infection: 
6 months. 
Respiratory 
tract 
infection: 
525/172 
Categories of 
25(OH) D 
(nmol/L):  
  <25; 
  25-74.9; 
  ≥75. 
 
Time: At birth 
Method: CLIA 
(Roche, 
Indianapolis, IN, 
USA) 
 
Blood sample: 
the newborn’s cord 
blood. 
 
Respiratory tract 
infection was 
diagnosed by 
pediatricians and 
pediatric allergy 
and pulmonology 
specialists. 
Multivitamin use 
during pregnancy, 
season of birth, and 
exposure to passive 
smoking during 
pregnancy. 
Respiratory tract infection: 
 at age 6 months 
[OR(95%CI)]: 
  3.56 (1.52 to 8.34); 
  2.06 (0.91 to 4.64); 
  1.00 (reference). 
   
Wills et al., 
The Avon 
Longitudinal Study 
of Parents and 
Children,  
2013, the UK26† 
52.0 Asthma: 
7.5 years. 
 
Wheeze: 
7.5 years. 
 
Asthma: 
3 177/379 
 
Wheeze: 
3 211/330 
Quintiles of 
25(OH) D 
(nmol/L): 
  <38; 
  38- 52; 
  52 -67; 
Time: any stage in 
pregnancy and the 
majority samples 
taken in the final 
trimester (52%). 
  
Children were 
defined as having 
current doctor-
diagnosed asthma 
if mothers 
responded 
Asthma and wheeze: 
Smoking, infections, 
anxiety score, 
antibiotic use, 
paracetamol use, 
BMI, alcohol intake, 
Asthma at age 7.5 
[OR(95%CI)]: 
  Q1:1.00 (reference); 
  O2:0.94 (0.71 to 1.26); 
  Q3:0.86 (0.64 to 1.14); 
  Q4:0.86 (0.64 to 1.15); 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
7 
 
   67- 89; 
  ≥89. 
Method: HPLC-MS. 
 
Blood sample: 
the mother’s serum. 
positively to the 
question: “Has a 
doctor ever 
actually said that 
your study child 
has asthma?” and 
positively to one or 
both of the 
questions on 
wheezing and 
asthma in the past 
12 months.  
 
Wheezing was 
defined as parents 
reported wheeze. 
educational level, 
housing tenure, 
financial difficulties, 
ethnicity, age, parity, 
history of asthma, 
eczema, rhino 
conjunctivitis, 
migraine, 
breastfeeding, 
daycare, pets, 
exposure to 
damp/mould in home, 
environmental 
tobacco smoke 
exposure, number of 
younger siblings, 
gestational age, birth 
weight, head 
circumference, birth 
length, BMI at age 7 
years and offspring 
serum 25(OH)D, sex 
and offspring age, and 
season of 
measurement. 
 
  Q5:1.00 (0.75 to 1.33). 
 
Wheeze at age 7.5 
[OR(95%CI)]: 
  Q1:1.00 (reference); 
  O2:0.94 (0.69 to 1.27); 
  Q3:0.84 (0.62 to 1.14); 
  Q4:0.84 (0.61 to 1.15); 
  Q5:1.06 (0.78 to 1.43). 
 
 
Baïz et al.,  
The EDEN 
Prospective Birth 
Cohort Study, 
2014, France36 
58.2 Asthma: 
5 years 
 
Wheeze: 
5 years 
 
 
 
Asthma: 
239/19 
 
Wheeze: 
239/93 
 
25(OH) D 
(nmol/L): 
continuous 
 
Time: At birth. 
 
Method: CLIA 
performed on the 
LIAISON platform 
(DiaSorin, Sallugia, 
Italy). 
 
Blood sample: 
the newborn’s cord 
blood. 
Asthma was 
defined as parental 
report of a doctor’s 
diagnosis of 
asthma plus either 
1 or more attacks 
of wheeze or use of 
asthma medication 
in the last 12 
months. 
 
Wheeze was 
Asthma and wheeze: 
City, mother’s age, 
maternal history of 
allergy, pre-
pregnancy BMI, any 
smoking during 
pregnancy, any 
passive smoke 
exposure during the 
first 3 years of life, 
number of siblings, 
household income, 
Per 12.5 nmol/L 
increment: 
 
Asthma at age 5  
[OR(95%CI)]: 
  1.07 (0.78 to 1.45). 
 
Different wheezing 
patterns 
[OR(95%CI)]: 
Early transient  
  0.67 (0.54 to 0.81). 
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defined as present 
if the parents 
answered yes to 
the following 
question: Has your 
child had wheezing 
or whistling in the 
chest in the 
preceding 12 
months?”
 
newborn’s sex and 
weight, season of 
birth, and exclusive 
breast-feeding for 4 
months or longer. 
 
Late onset  
  0.86 (0.67 to 1.11). 
Persistent  
  1.15 (0.79 to 1.691). 
 
 
Chawes et al.,  
The COPSAC2000 
Birth Cohort 
Study, 2014, 
Denmark24† 
48.2 Asthma: 
7 years 
 
Wheeze: 
7 years 
 
LRTI: 
3 years 
Asthma: 
199/31 
 
Wheeze: 
229/57 
 
LRTI: 
 204/116 
Categories of 
25(OH) D 
(nmol/L):  
  <50; 
  50-75; 
  >75. 
Time: at birth. 
 
Method: LC-MS 
[Calibrators 
traceable to NIST 
SRM 972 
Chromsystems, DE]. 
 
Blood sample: 
the newborn’s cord 
blood. 
Asthma 
is diagnosed 
according to 
international 
guidelines and was 
based on recurrent 
wheeze, including 
diary verified 
troublesome lung 
symptoms, 
symptoms judged 
by the COPSAC 
pediatricians to be 
typical of asthma; 
in need of 
intermittent rescue 
use of inhaled β2 
agonist; 
responding to a 3-
month trial of 
inhaled 
corticosteroids and 
relapsing when 
stopping treatment. 
 
Wheeze: recurrent 
wheeze was 
Asthma, wheeze and 
LRTI: 
Mother’s age at 
newborn’s birth, 
blood sampling 
season, older siblings, 
and hair nicotine level 
at age 1.  
Asthma at age 7 
[OR(95%CI)]: 
All: 
   1.63 (0.47 to 5.61); 
   1.20 (0.30 to 4.77); 
   1.00 (reference). 
Boys: 
   3.97 (0.38 to 42.06); 
   4.63 (0.38 to 56.62); 
   1.00 (reference). 
Girls: 
   1.05 (0.22 to 4.97); 
   1.64 (0.10 to 3.99); 
   1.00 (reference). 
 
Per 10 nmol/L decrement 
[OR(95%CI)]: 
All: 1.01 (0.84 to 1.19). 
Boys: 0.98 (0.72 to 1.34). 
Girls: 1.01 (0.82 to 1.25). 
 
 
Wheeze at age 7 
[OR(95%CI)]: 
All: 
   3.09 (1.06 to 9.04); 
   2.00 (0.64 to 6.24); 
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defined as 
troublesome lung 
symptoms 
≥4weeks or ≥5 
episodes of ≥3 
consecutive days 
within 6 months.     
  
 
LRTI: 
The diagnoses 
were established at 
the acute visits to 
the clinic by the 
research 
pediatricians based 
on clinical 
appearance 
regardless of 
identified 
pathogen(s) in 
accordance with 
predefined 
standard 
procedures or if the 
child had been 
hospitalized.  
    
   1.00 (reference). 
Boys: 
   8.60 (1.40 to 53.05); 
   10.39 (1.49 to 72.34); 
   1.00 (reference). 
Girls: 
   1.91 (0.46 to 7.93); 
   0.88 (0.18 to 4.31); 
   1.00 (reference). 
 
Per 10 nmol/L decrement 
[OR(95%CI)]: 
All: 0.90 (0.78 to 1.04). 
Boys: 0.86 (0.68 to 1.09). 
Girls: 0.93 (0.76 to 1.13). 
 
 
LRTI at age 7 
[OR(95%CI)]: 
All: 
  1.28 (0.55 to 2.96); 
  1.01 (0.42 to 2.43); 
  1.00 (reference). 
Boys: 
   2.21 (0.62 to 7.93); 
   1.42 (0.38 to 5.37); 
   1.00 (reference). 
Girls: 
   0.96 (0.29 to 3.17); 
   0.84 (0.24 to 2.92); 
   1.00 (reference). 
 
Per 10 nmol/L decrement 
[OR(95%CI)]: 
All: 0.90 (0.73 to 1.12). 
Boys: 0.86 (0.68 to 1.09). 
Girls: 1.01 (0.85 to 1.19). 
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de Jongh et al.,  
The Southampton 
Women’s Surve31 
 
NA Wheeze 
and LRTI: 
2 years 
Wheeze: 
1 876/484 
 
LRTI: 
1 875/382 
Categories of 
25(OH) D 
(nmol/L): 
  <25;  
  25-49;  
  50-74; 
  ≥75. 
Time: 34 
week gestation. 
 
Method: RIA 
(Diasorin, 
Stillwater, MN, 
USA). 
 
Blood sample: 
the mother’s serum. 
 
Parents reported 
wheeze and LRTI. 
Chest infection, 
bronchitis, 
bronchiolitis and 
pneumonia were 
combined into one 
variable labelled 
“LRTI”. 
Wheeze and LRTI: 
Child’s sex, 
birth weight and 
gestational age, 
and for maternal age 
at childbirth, 
educational level, pre-
pregnancy BMI, 
parity, ethnicity, 
smoking in 
pregnancy, and 
duration 
of breastfeeding. 
Wheeze at age 2 
[RR(95%CI)]: 
  0.85 (0.58 to 1.25); 
  1.01 (0.84 to 1.22); 
  0.92 (0.75 to 1.12); 
  1.00 (reference). 
 
Diagnosed LRTI at age 2 
[RR(95%CI)]: 
  0.69 (0.41 to 1.14); 
  0.98 (0.79 to 1.22); 
  0.92 (0.73 to 1.16); 
  1.00 (reference). 
 
Luczynska et al.,  
2014, Germany32 
51.2 LRTI: 
1 year 
LRTI: 
777/285 
Quartiles of 
25(OH) D 
(nmol/L) based 
on the season of 
blod collection 
standardized 
values: 
  <22.1; 
  22.1-<29.5; 
 29.5-<40.2; 
 ≥40.2. 
 
Time: At birth. 
 
Method: EIA  
(IDS, 
Immunodiagnostic 
systems Ltd, 
Boldon, UK). 
 
Blood sample: 
the newborn’s cord 
blood. 
 
Incidence of LRTI 
during the child’s 
first year of life 
was determined 
using a self-
administered questi
onnaire completed 
by the child’s 
physician during 
the 1 year follow-
up period. 
Sex, whether the child 
had a sibling under 5 
years of age, 
premature delivery, 
and breastfeeding 
duration. 
LRTI at age 1 
[RR(95%CI)]: 
  Q1:1.06 (0.82 to 1.37); 
  Q2:1.04 (0.79 to 1.36); 
  Q3:1.15 (0.89 to 1.48); 
  Q4:1.00 (reference). 
 
 
Zosky et al.,  
The Western 
Australian 
Pregnancy Cohort 
Study,  
2014, Australia11  
46.6 Asthma 
and 
wheeze: 
14 years 
Asthma and 
wheeze: 
288/NA 
Two level of 
25(OH) 
D (nmol/L): 
  ≤50; 
  >50. 
Time:16~20 week 
gestation; 
mean:18week. 
 
Method: EIA 
(Immunodiagnostic 
Systems; Scottsdale, 
AZ) 
 
Blood sample: 
the mother’s serum 
 
Current asthma 
was defined as a 
doctor diagnosis of 
asthma at any time, 
with wheeze and 
use of any asthma 
medication in the 
past 12 months. 
 
Current wheeze 
was defined by 
questionnaire at 
Asthma and wheeze: 
Maternal asthma, 
parental education, 
maternal age, birth 
order, maternal 
smoking, maternal 
alcohol consumption, 
breastfeeding, and 
femur length Z-score 
at 16 to 20 weeks’ 
gestation. 
 
Current asthma at age 14 
[OR(95%CI)]: 
All:  
  1.82 (0.79 to 4.17); 
  1.00 (reference). 
Boys:  
  1.53 (0.31 to 7.54); 
  1.00 (reference). 
Girls:  
  0.21 (0.01 to 3.51); 
  1.00 (reference). 
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each age (yes/no). Sex analysis:   
Factors above, Plus 
Tanner score. 
Current wheeze at age 14 
[OR(95%CI)]: 
All:  
  1.31 (0.63 to 2.75); 
  1.00 (reference). 
Boys:  
  1.54 (0.69 to 5.97); 
  1.00 (reference). 
Girls:  
  1.11 (0.42 to 2.94); 
  1.00 (reference). 
 
 
Chiu et al.,  
The PATCH study, 
2015, Taiwan38 
55.9 Asthma: 
4 years 
Asthma: 
186/26 
Two level of 
25(OH) 
D (nmol/L): 
<50; 
  ≥50. 
Time: At birth. 
 
Method: ECL 
(Roche Diagnostics, 
Mannheim, 
Germany). 
 
Blood sample: 
the newborn’s cord 
blood. 
Asthma was 
diagnosed as ever 
having asthma 
with the 
occurrence of 
wheeze or current 
use of asthma 
medication. 
Maternal age at 
delivery, maternal 
history of atopy, 
paternal history of 
atopy, any passive 
smoke exposure 
during pregnancy, any 
older siblings, 
household income, 
gestational age, sex, 
and exclusive breast-
feeding for 6 months 
or longer. 
 
Asthma at age 4 
[OR(95%CI)]: 
  2.27(0.98 to 5.28); 
  1.00(reference). 
 
Jones et al.,  
2015, Australia39 
55.6 Wheeze: 
2.5 years 
Wheeze: 
139/34 
25(OH) D 
(nmol/L): 
continuous 
 
Time: At birth. 
 
Method: LC-MS 
(RDDT, Melbourne, 
Vic., Australia). 
 
Blood sample: 
the newborn’s cord 
blood and peripheral 
blood at 6 months. 
Parents reported 
wheeze. Questions 
regarding wheeze 
were based on the 
international study 
of asthma and 
allergies in 
childhood phase on 
questionnaire.  
Sex and season of 
birth. 
Wheeze at age 2.5 
[OR(95%CI)]: 
 
Per 10 nmol/L increment 
in cord 25(OH) D level: 
  0.95 (0.77 to 1.18). 
 
Per 10 nmol/L increment 
in peripheral blood 
25(OH) D level: 
  0.83 (0.67 to 1.02). 
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Stelmach et al.,  
The Polish Mother 
and Child Cohort 
Study, 
2015, Poland44 
NA Multi- 
triggered 
wheezing 
and  
respiratory 
infection: 
2 years 
Multi- 
triggered 
wheezing: 
188/22 
 
respiratory 
infection: 
159/62 
Two levels of 
25(OH) D 
(nmol/L):  
  <10.4; 
  ≥10.4. 
Time: At birth. 
 
Method: HPLC 
(produced by 
ChromosystemsR). 
 
Blood sample: 
the newborn’s cord 
blood. 
 
Multi-triggered 
wheezing was 
defined as 
wheezing triggered 
by two or more 
factors (e.g., viral 
infection, weather, 
and activity). 
 
Respiratory 
infections were 
defined as episodes 
of cold without 
wheezing. 
Wheeze and 
respiratory infection: 
number of infections 
and paternal smoking. 
Multi-triggered wheezing 
at age 2 [OR(95%CI)]: 
  2.81 (1.13 to 7.00); 
  1.00 (reference). 
Per 2.5 nmol/L increment 
[OR(95%CI)]: 
  0.20 (0.02 to 1.71). 
 
Respiratory infections at 
age 2 [OR(95%CI)]: 
  0.95 (0.46 to 1.96); 
  1.00 (reference). 
Per 2.5 nmol/L increment 
[OR(95%CI)]: 
 1.52 (0.33 to 6.94). 
25(OH) D, 25-Hydroxyvitamin D; AZ, Arizona; BMI, body mass index; CI, confidence interval; CLIA, chemiluminescence immunoassay; COCOA, The COhort for Childhood 
Origin Asthma and allergic disease; COPSAC, COpenhagen Prospective Study on Asthma in Childhood; ECL, electrochemiluminescence; EDEN, Étude sur les Déterminants pré- 
et postnatals précoces du développement psychomoteur et de la santé de l’Enfant (Pre- and postnatal determinants of child growth, development and health); EIA, enzyme 
immunoassay; HPLC, high-performance liquid chromatography; HPLC-MS, high-performance liquid chromatograpy-tandem mass spectrometry; IDS Ltd, immunodiagnostic 
systems limited; INMA, the INfancia y Medio Ambiente (Environment and Childhood); LC-MS, liquid chromatography-tandem mass spectrometry; LRTI, lower respiratory tract 
infection; MN, Minnesota; NA, not available; OR, odds ratio; PATCH, birth cohort in the Prediction of Allergies in Taiwanese CHildren; Q, quartile/quintile; RIA, 
radioimmunoassay; RR, relative risk; T, tertile; UK, United Kingdom; USA, the United States of America.  
*Only season was adjusted.   
†We got de novo results for these studies.
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E Table 3. Multivariable adjusted associaiton of 25 (OH) D with risk of asthma, wheeze, and respiratory tract 
infection using a fixed-effects model: a sensitivity analysis 
Outcome Odds Ratio (95%CI) 
Highest vs. lowest Per 10 nmol / L increment 
Asthma 0.85 (0.72 to 1.001) 0.99 (0.97 to 1.02) 
Wheeze 0.85 (0.72 to 0.996) 0.98 (0.97 to 1.003) 
Respiratory tract infection 0.93 (0.91 to 0.95) 0.97 (0.94 to 1.01) 
25(OH) D, 25-Hydroxyvitamin D; CI, confidence interval; OR, odds ratio. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
14 
 
E Table 4. Influence of a single study on the pooled associaiton of 25 (OH) D with risk of asthma, wheeze, and 
respiratory tract infection using a random-effects model: a sensitivity analysis 
Outcome Study omitted Odds Ratio (95%CI) 
Highest vs. lowest Per 10 nmol / L increment 
Asthma None 0.84 (0.70 to 1.01) 0.99 (0.97 to 1.02) 
Camargo et al, 201137 0.82 (0.67 to 0.999) 0.99 (0.97 to 1.02) 
Rothers et al, 201142 -- 0.99 (0.97 to 1.02) 
Morales et al, 201241 0.82 (0.66 to 1.03) 0.996 (0.97 to 1.02) 
Pike et al, 201225 0.82 (0.67 to 1.002) 0.997 (0.97 to 1.02) 
Magnus et al, 201310 0.91 (0.75 to 1.10) 1.00 (0.98 to 1.03) 
Wills et al, 201326 0.78 (0.64 to 0.96) 0.99 (0.96 to 1.03) 
Baïz et al, 201436 -- 0.99 (0.97 to 1.02) 
Chawes et al, 201424 0.84 (0.69 to 1.03) 0.99 (0.97 to 1.02) 
Zosky et al, 201411 0.86 (0.71 to 1.03) -- 
Chiu et al, 201538 0.87 (0.74 to 1.03) -- 
Wheeze None 0.77 (0.58 to 1.03) 0.98 (0.96 to 1.004) 
Camargo et al, 201137 0.88 (0.68 to 1.13) 0.99 (0.97 to 1.02) 
Morales, 201241 0.73 (0.52 to 1.04) 0.98 (0.96 to 1.01) 
Pike et al, 201225 0.73 (0.51 to 1.04) 0.98 (0.95 to 1.003) 
Wills et al, 201326 0.72 (0.51 to 1.005) 0.97 (0.95 to 0.9996) 
Baïz et al, 201436 -- 0.98 (0.96 to 1.004) 
Chawes et al, 201424 0.82 (0.61 to 1.09) 0.99 (0.97 to 1.01) 
de Jongh et al, 201431 0.72 (0.53 to 0.99) 0.98 (0.96 to 1.01) 
Zosky et al, 201411 0.77 (0.56 to 1.06) -- 
Jones et al, 201539 -- 0.98 (0.96 to 1.01) 
Stelmach et al, 201544 0.82 (0.62 to 1.10) 0.98 (0.97 to 1.01) 
Respiratory tract infection None 0.85 (0.66 to 1.09) 0.97 (0.94 to 1.01) 
Camargo et al, 201137 0.90 (0.70 to 1.15) 0.98 (0.94 to 1.01) 
Morales et al, 201241 0.88 (0.66 to 1.18) 0.99 (0.95 to 1.04) 
Pike et al, 201225 0.78 (0.61 to 1.01) 0.95 (0.91 to 0.99) 
Magnus et al, 201310 -- 0.98 (0.94 to 1.02) 
Mohamed et al, 201340 0.82 (0.58 to 1.18) -- 
Shin et al, 201343 0.90 (0.72 to 1.13) 0.98 (0.94 to 1.01) 
Chawes et al, 201424 0.85 (0.65 to 1.11) 0.97 (0.93 to 1.01) 
de Jongh et al, 201431 0.80 (0.62 to 1.04) 0.97 (0.93 to 1.01) 
Luczynska et al, 201432 0.84 (0.63 to 1.11) 0.97 (0.93 to 1.01) 
Stelmach et al, 201544 0.83 (0.63 to 1.09) 0.97 (0.94 to 1.01) 
25(OH) D, 25-Hydroxyvitamin D; CI, confidence interval; OR, odds ratio. 
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E Table 5 Summary of levels of 25(OH)D in the included studies in this meta-analysis 
 
Source Average (range) 
of 25(OH)D, nmol/L 
Lowest category 
of 25(OH)D 
Highest category 
of 25(OH)D 
 
Levels 
(nmol/L) 
% of 
participants 
Levels 
(nmol/L) 
% of 
participants 
Camargo et al., 201137 44 (~5 to ~290) <25 19.5 ≥75 27.2 
Rothers et al., 201142 ~68 (13 to  172.5)* <50 26.5 ≥75 (≥100) 32.5 (11.0) 
Morales et al., 201241 75.75 (14.25 to 227.5) <54.75 ~25.0 ≥92.75 24.8 
Pike et al., 201225 59 (10.4 to 203)* <46 33.3 ≥74 33.3 
Magnus et al., 201310 73.3 (NA) ≤50 18.9 >75 46.1 
Mohamed et al., 201340 60.1 (17.4 to 80.4) ≤30 12.1 ≥75 43.7 
Shin et al., 201343 38.2 (11.9 to 1200) <25 34.3 ≥75 10.1 
Wills et al., 201326 61.5 (8.5 to 240.5)* <38 16.5 ≥89 21.3 
Baïz et al., 201436 44.5 (6 to 120) <25 ~23.5* ≥75 ~15.0* 
Chawes et al., 201424 47.6 (10 to 145) <50 53.0 ≥75 15.0 
de Jongh et al., 201431 59.0 (43 to 88) <25 5.1 ≥75 34.3 
Luczynska et al., 201432 29.5 (up to ~100) <25 46.1 ≥50 17.4 
Zosky et al., 201411 58.0 (NA) <50 34.9 ≥75 18.8 
Chiu et al., 201538 59.5 (up to ~135) <50 58.0 ≥50( ≥75*) 42.0 (~20.0*) 
Jones et al., 201539 57.9 (20 to ~120)* <50 NA ≥75 >50.0 
Stelmach et al., 201544 15.8 (up to ~70)* <10.4 25.0 ≥75 0.0 
25(OH) D, 25-Hydroxyvitamin D; NA, not available. 
 *de novo results.  
 
 
